Anti-TCF3 / E2A (phospho T355) antibody (ab85772)

Overview

  • Product nameAnti-TCF3 / E2A (phospho T355) antibody
    See all TCF3 / E2A primary antibodies
  • Description
    Rabbit polyclonal to TCF3 / E2A (phospho T355)
  • Tested applicationsSuitable for: WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Mouse, Rat, Hamster, Dog
  • Immunogen

    Synthetic peptide conjugated to KLH derived from within residues 350 - 450 of Human TCF3/ E2A, phosphorylated at T355.

    (Peptide available as ab103576.)

  • Positive control
    • This antibody gave a positive signal in both HeLa and HepG2 whole cell lysates.

Properties

Applications

Our Abpromise guarantee covers the use of ab85772 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Detects a band of approximately 80 kDa (predicted molecular weight: 68 kDa).

Target

  • FunctionHeterodimers between TCF3 and tissue-specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Dimers bind DNA on E-box motifs: 5'-CANNTG-3'. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer.
  • Involvement in diseaseNote=Chromosomal aberrations involving TCF3 are cause of forms of pre-B-cell acute lymphoblastic leukemia (B-ALL). Translocation t(1;19)(q23;p13.3) with PBX1; Translocation t(17;19)(q22;p13.3) with HLF. Inversion inv(19)(p13;q13) with TFPT.
  • Sequence similaritiesContains 1 basic helix-loop-helix (bHLH) domain.
  • Domainthe 9aaTAD motif is a transactivation domain present in a large number of yeast and animal transcription factors.
  • Post-translational
    modifications
    Phosphorylated following NGF stimulation.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • AGM8 antibody
    • bHLHb21 antibody
    • Class B basic helix-loop-helix protein 21 antibody
    • E12 antibody
    • E2A antibody
    • E2A immunoglobulin enhancer binding factors E12/E47 antibody
    • E47 antibody
    • Helix loop helix protein HE47 antibody
    • Immunoglobulin enhancer-binding factor E12/E47 antibody
    • Immunoglobulin transcription factor 1 antibody
    • ITF1 antibody
    • Kappa-E2-binding factor antibody
    • MGC129647 antibody
    • MGC129648 antibody
    • Negative vitamin D response element binding protein antibody
    • NOL1-TCF3 fusion antibody
    • TCF-3 antibody
    • Tcf3 antibody
    • TFE2_HUMAN antibody
    • transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47) antibody
    • Transcription factor 3 antibody
    • transcription factor 3 variant 3 antibody
    • Transcription factor E2-alpha antibody
    • Transcription factor ITF-1 antibody
    • VDIR antibody
    • VDR interacting repressor antibody
    • vitamin D receptor-interacting repressor antibody
    see all

Anti-TCF3 / E2A (phospho T355) antibody images

  • All lanes : Anti-TCF3 / E2A (phospho T355) antibody (ab85772) at 1 µg/ml

    Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate
    Lane 2 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate
    Lane 3 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate with Human TCF3 / E2A peptide (ab118180) at 1 µg/ml
    Lane 4 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate with Human TCF3 / E2A peptide (ab118180) at 1 µg/ml
    Lane 5 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate with Human TCF3 / E2A (phospho T355) peptide (ab103576) at 1 µg/ml
    Lane 6 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate with Human TCF3 / E2A (phospho T355) peptide (ab103576) at 1 µg/ml

    Lysates/proteins at 10 µg per lane.

    Secondary
    Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
    Developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 68 kDa
    Observed band size : 80 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 40 kDa. We are unsure as to the identity of these extra bands.

    Exposure time : 20 minutes

References for Anti-TCF3 / E2A (phospho T355) antibody (ab85772)

ab85772 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab85772.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"